September 27, 2026 · AxonCPT Team · billing, ADHD assessment, CPT

Is ADHD CPT Testing Covered by Insurance? 2026 Payer Rules

Sometimes, but not reliably. Commercial payers often cover a psychological or neuropsychological evaluation when their medical-necessity criteria are met. A standalone continuous performance test (CPT) for ADHD is a different matter. Aetna’s ADHD policy lists “computerized tests of attention and vigilance (continuous performance tests)” as experimental, investigational, or unproven for ADHD [1]. Evernorth’s neuropsychological testing policy, effective September 15, 2026, does not list ADHD among its covered indications [2]. Other payers are broader. Check the patient’s specific plan before you test.

Calculator and laptop on a desk, representing insurance coverage review for ADHD testing Photo by Jakub Żerdzicki on Unsplash

This article summarizes public payer policies as published on the dates shown. It is educational and is not billing, coding, or legal advice. Policies change and vary by plan, state, and line of business. Confirm coverage with each payer before testing. CPT® is a registered trademark of the American Medical Association.

Coverage vs. code selection: two different questions

Two questions come up whenever a prescriber adds an objective attention test. The first is which code describes the service. The second is whether the patient’s plan will pay for it. This post covers only the second. For code selection, see our ADHD testing CPT code guide. For whether a nurse practitioner can bill the testing codes at all, see can nurse practitioners bill 96130?

Coverage turns on three things:

  1. The payer’s clinical policy. Most large payers publish these policies, and they state which indications are medically necessary and which technologies they consider unproven.
  2. The member’s benefit plan. Some plans exclude educational testing, carve out behavioral health to a separate vendor, or require prior authorization.
  3. Your documentation. Even under a favorable policy, the record has to show why testing was needed and how the result will change management.

What Aetna’s ADHD policy says (CPB 0426)

Aetna Clinical Policy Bulletin 0426, Attention Deficit/Hyperactivity Disorder, was last reviewed on July 7, 2026. Its next review is scheduled for April 22, 2027 [1]. Here is what it says:

  • Continuous performance tests. Under “Experimental, Investigational, or Unproven,” the assessment list includes “Computerized tests of attention and vigilance (continuous performance tests) (eg, Gordon Diagnostic System)” and, separately, the “Quotient ADHD system/test” [1].
  • Psychological testing. “Psychological testing is not considered medically necessary for evaluation of children with uncomplicated cases of ADHD” [1].
  • Neuropsychological testing. This may be medically necessary “in neurologically complicated cases of ADHD (e.g., post head trauma, seizures),” or to distinguish ADHD from learning disabilities or language disorders when history and examination leave the question open. It is “not considered medically necessary for the clinical evaluation of persons with uncomplicated cases of ADHD” [1].
  • Code tables. The bulletin lists 96130–96131 under “CPT codes not covered for indications listed in the CPB.” It lists 96132, 96136–96139, and 96146 under “CPT codes covered if selection criteria are met” [1]. The selection criteria are the neuropsychological ones above, and the bulletin refers readers to CPB 0158 for testing in general.

What this means in practice: under this Aetna policy, a CPT given to support an uncomplicated ADHD diagnosis falls in the unproven category. Services Aetna does list as medically necessary for ADHD assessment include a complete psychiatric evaluation for adults and DSM-5-based interviews [1].

What Evernorth/Cigna’s 2026 policy says (EN0258)

Evernorth Coverage Policy EN0258, Neuropsychological Testing, took effect September 15, 2026, and is next due for review on May 15, 2027 [2]. According to its revision history, the September 2026 update was a focused review with “no clinical policy statement changes” [2]. Here is what it says:

  • Neuropsychological testing is medically necessary when all of these are true: the information will be used for clinical decision-making, there are “symptoms indicative of a significant decline in cognitive or behavioral functioning,” and there is reasonable suspicion of one of the listed conditions [2]. The list includes autism spectrum disorder, dementia, epilepsy, traumatic brain injury, stroke, and others. ADHD is not on it.
  • Testing “is not covered or reimbursable for any indication not listed above,” including when it is used primarily for screening, baseline assessment, or monitoring of chronic conditions when there is no significant new change [2].
  • “Computerized neuropsychological testing for any indication that does not require a physician, psychologist, or licensed mental health professional to provide interpretation and preparation of a report is considered experimental, investigational or unproven” [2].

Two points of scope matter here. First, the policy’s ICD-10 table does include F90.0–F90.9 (ADHD) among the diagnosis codes listed with the covered procedure codes [2]. That listing does not override the narrative criteria, but it means an ADHD diagnosis code on a claim is not automatically excluded when a listed indication also applies. Second, EN0258 addresses neuropsychological testing. It doesn’t tell you how a given Cigna plan handles psychological testing (96130) for ADHD under a behavioral health benefit. Confirm that with the plan.

A broader example: BCBS Florida

Payers do not all take the same line. Florida Blue’s Medical Coverage Guideline 01-95805-14, Neuropsychological Testing (reviewed February 26, 2026, and revised March 15, 2026), lists among its medically necessary indications testing to “evaluate primary symptoms of impaired attention and concentration that can occur in many medical and psychiatric conditions” [3].

The same guideline says testing is not medically necessary when a battery is “comprised exclusively of self-administered, self-created, or self-scored inventories,” when it is used as a routine screening tool without clinical justification, or when repeat testing “is not required for medical or clinical decision-making” [3]. It also expects “an initial face-to-face complete diagnostic assessment” and a battery that is “standardized and has nationally accepted validity and reliability” [3].

What about Medicare?

For Medicare, testing coverage runs through Medicare Administrative Contractor (MAC) policies and CMS guidance, not a single ADHD rule. Points relevant to prescribers:

  • Reason for testing. One MAC, Wisconsin Physicians Service, requires that “the medical record must document the reason the tests are being performed” (Billing and Coding Article A57481) [4].
  • 96146 is billed once. CMS’s testing FAQ says the computer-administered code (96146) “is billed once regardless of the time spent completing the tests” [5].
  • Supervision. CMS says only physicians or clinical psychologists may provide general supervision for diagnostic psychological and neuropsychological tests. When NPs personally perform these tests, supervision follows the collaboration rules of their benefit category [5]. PMHNPs who plan to use technician-administered codes should read this carefully.

Payer policies at a glance

Payer / policy Date shown What it says about CPTs or testing for ADHD
Aetna CPB 0426 [1] Last review 07/07/2026; next 04/22/2027 CPTs listed as experimental/investigational/unproven for ADHD; psych testing not medically necessary for uncomplicated pediatric ADHD
Evernorth EN0258 [2] Effective 09/15/2026; next review 05/15/2027 ADHD not among listed neuropsych indications; computerized testing without clinician interpretation and report is unproven
Florida Blue 01-95805-14 [3] Revised 03/15/2026 Covers evaluation of “primary symptoms of impaired attention and concentration” when criteria are met
Medicare (WPS A57481; CMS FAQ) [4][5] Varies by MAC Documented reason for testing required; 96146 billed once; supervision rules for NPs

Try it with your next patient. AxonCPT gives you 2 free tests every month — no card required. Send a link, your patient finishes in ~16 minutes from home, and you get a norm-referenced report instantly. Create your free account →

Why payers are cautious about CPTs

Payer skepticism tracks the research. A 2024 systematic review in The Clinical Neuropsychologist examined 69 studies of the Conners CPT, T.O.V.A., Gordon Diagnostic System, and IVA in adults with ADHD. It found that most studies had a high risk of bias and that the CPTs reviewed “appeared to have limited diagnostic utility and classification accuracy” [6]. Its conclusion: CPTs “should not be used in isolation as a diagnostic test but may be beneficial when used as a component of a comprehensive assessment” [6].

That fits how most prescribers already use a CPT. It supplies objective data alongside the interview, history, rating scales, and collateral information, and it is especially useful for tracking change at dose adjustments. It is not a standalone diagnostic test. Your documentation should make that role explicit.

What PMHNPs and telehealth prescribers can do

  1. Verify benefits before testing. Ask whether psychological or neuropsychological testing requires prior authorization, which policy applies, and whether behavioral health is carved out.
  2. Separate diagnosis from monitoring. Coverage criteria for a diagnostic evaluation and for repeat measurement during titration are often different. Evernorth excludes monitoring when there is no significant new change [2]. Florida Blue excludes repeat testing that isn’t needed for clinical decisions [3].
  3. Document the clinical question. Record why you tested, what the result showed, and what you decided because of it. Our guide to ADHD documentation for stimulant prescribing shows how that record also supports the prescription.
  4. Plan for non-coverage. Many practices treat a standalone CPT as an unreimbursed practice cost or a self-pay item. If you do that, follow your payer contracts and state rules on billing members for non-covered services. For the cost side, see what objective ADHD testing costs clinicians.

How this looks in practice

Consider a telehealth PMHNP seeing an adult with suspected ADHD who has Aetna coverage.

  1. Intake. A psychiatric diagnostic evaluation, rating scales, and collateral history. These are the parts Aetna’s policy lists as medically necessary [1].
  2. Objective measure. The prescriber decides a standardized attention measure will help, both as a baseline and to track dose changes. Because the plan’s policy treats CPTs as unproven for ADHD, the practice absorbs the cost or offers it as self-pay. With objective ADHD testing with AxonCPT, the prescriber sends a link, and the patient completes the test in about 16 minutes on a phone, tablet, or computer, with no app or login. The report arrives immediately, with five metrics compared against age- and sex-matched norms from a 20,000+ reference dataset.
  3. Decision. The result is weighed with everything else, and the note records how it informed the decision.
  4. Follow-up. The test is repeated at dose changes, and the note gives the reason for each retest.

You can see what the report looks like before deciding whether it fits this workflow. This article makes no claim about whether any payer covers AxonCPT or any other specific product.

Frequently asked questions

Is ADHD testing covered by insurance? A diagnostic evaluation for ADHD often is, subject to the plan’s criteria. Standalone computerized CPTs are less consistently covered. Aetna lists them as experimental for ADHD [1], and Evernorth’s neuropsychological policy does not list ADHD as an indication [2]. Check the specific plan.

Does insurance cover QbTest, TOVA, or Conners CPT 3? None of the policies reviewed here names those products as covered. Aetna’s policy groups continuous performance tests in its unproven list for ADHD [1]. Coverage depends on the plan, the indication, and how the service is billed. Ask the payer directly.

Is repeat CPT testing during titration covered? It is often harder to get covered than an initial evaluation. Evernorth excludes monitoring without significant new change [2], and Florida Blue excludes repeat testing that isn’t needed for clinical decisions [3]. Document the clinical reason for each retest.

Does Medicare cover ADHD testing? Medicare covers psychological and neuropsychological testing when it is reasonable and necessary under the applicable MAC policy. For example, WPS requires the record to document why the tests were performed [4]. Supervision and code rules apply [5].

Start testing your patients with AxonCPT

When coverage for a standalone CPT is uncertain, a predictable per-test cost matters. AxonCPT gives you 2 free tests every month with no card required. After that, list prices on axoncpt.com are $49 for 5 tests, $149 for 20, or $79/month unlimited (accessed September 27, 2026). Create your free AxonCPT account or learn more at axoncpt.com.

References

  1. Aetna. Clinical Policy Bulletin 0426: Attention Deficit/Hyperactivity Disorder. Last review July 7, 2026; next review April 22, 2027. Accessed September 27, 2026.
  2. Evernorth Health Services. Coverage Policy EN0258: Neuropsychological Testing. Effective September 15, 2026; next review May 15, 2027.
  3. Florida Blue. Medical Coverage Guideline 01-95805-14: Neuropsychological Testing. Reviewed February 26, 2026; revised March 15, 2026.
  4. Wisconsin Physicians Service Insurance Corporation. Billing and Coding: Psychological and Neuropsychological Testing (A57481). CMS Medicare Coverage Database. Accessed September 27, 2026.
  5. Centers for Medicare & Medicaid Services. Diagnostic Psychological and Neuropsychological Tests FAQs. Accessed September 27, 2026.
  6. Varela JL, Magnante AT, Miskey HM, Ord AS, Eldridge A, Shura RD. A systematic review of the utility of continuous performance tests among adults with ADHD. Clin Neuropsychol. 2024;38(7):1524–1585.